secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001140361-23-000651
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano Genomics reports preliminary Q4 revenue $8.1-8.4M, up 27-33% YoY
------------------------------------------------------------------------

- Full-year 2022 revenue expected $27.7-28.0M, up 54-56% vs 2021; exceeded initial guidance ranges.
- Installed base of Saphyr systems reached 240 at year-end, a 46% increase over 2021.
- Completed acquisition of Purigen Biosystems to accelerate OGM adoption via improved DNA prep.
- Planned commercial launch of next-gen OGM system in H1 2023; NxClinical v7.0 release also expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000114036123000651/0001140361-23-000651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000114036123000651/brhc10046334_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-000651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer